Home›Diabetes & Endocrinology› Tirzepatide reduces inflammatory markers and improves metabolic biomarkers in patients with obesity
Tirzepatide reduces inflammatory markers and improves metabolic biomarkers in patients with obesityTirzepatide reduces markers of inflammation in people with obesity
Journal of the American College of CardiologyPublished August 12, 2026Study authors: Sattar Naveed, Linetzky Bruno, Ruotolo Giacomo, Verma Subodh, Sourij Harald, Wang Hui, Vanderman Kad…PubMed ↗NCT04184622 ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that tirzepatide is associated with significant reductions in several biomarkers of inflammation and hepatic stress.
This study was a randomized controlled trial involving 392 participants with overweight or obesity. The primary objective of the investigation was to assess changes in log-transformed biomarker levels over a follow-up period of 72 weeks. The researchers conducted a post hoc analysis of these data to evaluate various metabolic and inflammatory markers.
The study compared tirzepatide at three different dosages (5 mg, 10 mg, or 15 mg administered once-weekly) against a placebo. These doses were evaluated for their impact on a wide range of biomarkers related to inflammation, lipid metabolism, and hepatic function.
Primary results focused on the change in log-transformed biomarker levels at 72 weeks. While specific primary outcome values are not detailed individually in the summary, several secondary outcomes showed significant improvements compared to placebo. High-sensitivity C-reactive protein (hs-CRP) decreased by -36.9% at 5 mg, -46.9% at 10 mg, and -54.6% at 15 mg (P < 0.05). Interleukin-6 (IL-6) showed reductions of -25.4% (5 mg), -27.8% (10 mg), and -30.2% (15 mg) (P < 0.05). Leukocytes were reduced by -8.6% at 5 mg, though this was not significant for the 5 mg dose; however, a reduction of -10.0% at 15 mg was statistically significant (P < 0.05).
Additional metabolic and hepatic markers also showed significant improvements. Leptin levels decreased by -44.4% (5 mg), -59.3% (10 mg), and -61.4% (15 mg) (P < 0.05). Gamma-glutamyl transferase was reduced by -18.6% (5 mg), -21.6% (10 mg), and -32.7% (15 mg) (P < 0.05). Fibroblast growth factor-21 decreased by -27.4% (5 mg), -27.6% (10 mg), and -39.9% (15 mg) (P < 0.05). Conversely, adiponectin levels increased significantly: 21.1% (5 mg), 35.1% (10 mg), and 47.7% (15 mg) (P < 0.05). E-selectin was reduced by -12.6% (5 mg), -20.0% (10 mg), and -26.4% (15 mg) (P < 0.05). Plasminogen activator inhibitor-1:Ag decreased by -41.4% (5 mg), -35.6% (10 mg), and -44.3% (15 mg) (P < 0.05).
Certain markers showed dose-specific significance. Free fatty acids were reduced by -17.1% only at the 15 mg dose (P < 0.05); results for 5 mg and 10 mg were not significant. Soluble intercellular adhesion molecule-1 was reduced by -9.7% (10 mg) and -11.1% (15 mg) (P < 0.05), but was not significant at 5 mg. Platelets were reduced by -6.0% only at the 15 mg dose (P < 0.05); results for 5 mg and 10 mg were not significant. No consistent associations were observed for fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.
Safety and tolerability data, including specific adverse event rates or discontinuation figures, were not reported. The study's primary limitation is that it is a post hoc analysis, which can increase the risk of type 1 errors and may limit the generalizability of the findings compared to a pre-specified primary analysis.
Clinically, these results suggest that tirzepatide is associated with improvements in biomarkers of metabolic, adiposity, and hepatic stress. It also appears to impact markers of inflammation and hemostasis/thrombosis. These findings may be relevant for patients with type 2 diabetes and obesity who require management of systemic inflammation. However, because this is a post hoc analysis, the evidence is of moderate certainty. Questions remain regarding the long-term clinical impact of these specific biomarker changes on hard outcomes like cardiovascular events or progression of liver disease.
How this fits prior evidence
How this fits prior evidence
This finding expands upon existing knowledge regarding metabolic inflammation in Type 2 Diabetes. While previous evidence noted that BCAA metabolism modulation may improve insulin sensitivity and alleviate metabolic inflammation, this study provides specific data on how tirzepatide impacts a broad range of inflammatory markers like IL-6 and hs-CRP. It also addresses the management of metabolic stress in patients with obesity.
Living with obesity or type 2 diabetes often involves more than just managing weight. These conditions can trigger chronic inflammation in the body, which is a state where the immune system stays active and can cause stress to organs like the heart and liver. For many people, finding ways to calm this internal stress is a major goal for long-term health.
To better understand how the medication tirzepatide affects these processes, researchers looked at data from a study involving 392 people who were overweight or had obesity. Participants took different doses of tirzepatide (5 mg, 10 mg, or 15 mg) once a week for 72 weeks, while others received a placebo. The team specifically looked at biomarkers, which are substances in the blood that act as signals for what is happening inside the body.
The results showed that tirzepatide led to significant drops in several markers of inflammation and metabolic stress compared to the placebo. For example, high-sensitivity C-reactive protein (a common marker for inflammation) dropped by up to 54.6% at the highest dose. Other markers like interleukin-6 and leptin also decreased significantly across all doses. Additionally, levels of adiponectin—a substance that helps regulate metabolism—increased as the dosage went up. These changes suggest the medication may help reduce the physical stress caused by excess fat on the body's systems.
It is important to keep these findings in perspective. This specific analysis was a post-hoc study, which means researchers looked back at data already collected from a larger trial to find these specific patterns. While the results are promising for understanding how tirzepatide works, they come from a single study's data set. Not every marker showed a change; for instance, some markers related to blood clotting and fat levels only showed significant changes at the highest dose of 15 mg.
For patients today, this means that while tirzepatide is known to help with weight and blood sugar, it may also be doing work behind the scenes to lower internal inflammation. However, because this was a post-hoc analysis, these findings are not yet enough to change standard medical advice immediately. Patients should continue to work closely with their doctors to see how these medications fit into their specific health plans.
What this means for you:
Tirzepatide may reduce markers of inflammation and metabolic stress in people with obesity and type 2 diabetes.
BACKGROUND: Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes and obesity. The effect of tirzepatide on cardiovascular risk biomarkers in people with overweight or obesity remains uncertain.
OBJECTIVES: The purpose of this study was to evaluate the association of tirzepatide compared to placebo on biomarkers that reflect inflammation (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, leukocytes), metabolic/adiposity/hepatic stress (homeostatic model assessment of insulin resistance, leptin, gamma-glutamyl transferase, fibroblast growth factor-21, adiponectin, free fatty acids), endothelial dysfunction (soluble intercellular adhesion molecule-1, E-selectin), and hemostasis/thrombosis (plasminogen activator inhibitor-1:antigen [Ag], tissue plasminogen activator:Ag, thrombomodulin, platelets) in people with obesity.
METHODS: The aforementioned biomarkers were assayed from plasma samples, collected at baseline, 24 weeks, and 72 weeks, from 100 randomly selected participants from each group of the SURMOUNT-1 trial who completed treatment with once-weekly placebo or tirzepatide 5, 10, or 15 mg (n = 392 after low sample volumes excluded). The change in each log-transformed biomarker level over time was evaluated by a mixed model for repeated measures, with change at 72 weeks the primary outcome of interest. Model estimates were back-transformed to the original (geometric mean ratio) scale and expressed as percent change in geometric means. Pearson correlations between log change in biomarker levels and weight were done on pooled tirzepatide doses.
RESULTS: At week 72, tirzepatide was associated with significantly greater reductions (negative values) or increases (positive values) in biomarker geometric means compared with placebo. For the 5-, 10-, or 15-mg doses, respectively, these included high-sensitivity C-reactive protein (-36.9%, -46.9%, -54.6%), interleukin-6 (-25.4%, -27.8%, -30.2%), leukocytes (not significant [NS], -8.6%, -10.0%), homeostatic model assessment of insulin resistance (-26.4%, -35.5%, -39.1%), leptin (-44.4%, -59.3%, -61.4%), gamma-glutamyl transferase (-18.6%, -21.6%, -32.7%), fibroblast growth factor-21 (-27.4%, -27.6%, -39.9%), adiponectin (21.1%, 35.1%, 47.7%), free fatty acids (NS, NS, -17.1%), soluble intercellular adhesion molecule-1 (NS, -9.7%, -11.1%), E-selectin (-12.6%, -20.0%, -26.4%), plasminogen activator inhibitor-1:Ag (-41.4%, -35.6%, -44.3%), and platelets (NS, NS, -6.0%) (all adjusted P < 0.05). No consistent associations were observed between tirzepatide and changes in fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.
CONCLUSIONS: In this post hoc analysis, tirzepatide was associated with improvements in biomarkers of metabolic/adiposity/hepatic stress and endothelial dysfunction, as well as selected biomarkers of inflammation and hemostasis/thrombosis. This analysis provides a comprehensive, long-term, randomized assessment of biomarker changes across multiple cardiovascular pathways during tirzepatide treatment in obesity. (A Study of Tirzepatide [LY3298176] in Participants With Obesity or Overweight [SURMOUNT-1]; NCT04184622).
